Hyperfine, Inc. (HYPR) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Hyperfine, Inc. is a health technology company developing the Swoop® Portable MR Imaging System, an AI-powered, ultra-low-field (ULF) magnetic resonance device for brain imaging. The company operates as a single business segment focused on the production, supply, and commercialization of the Swoop® system. In May 2025, the company received FDA 510(k) clearance for its next-generation Swoop® system powered by Optive AI™ software.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $2,696 | $3,631 | $4,833 | $6,926 |
| Gross Margin | $1,328 (49.3%) | $1,803 (49.7%) | $2,211 (45.7%) | $3,157 (45.6%) |
| Net Loss | $(9,225) | $(10,156) | $(18,643) | $(20,004) |
| Operating Cash Flow | N/A | N/A | $(17,159) | $(21,893) |
| Cash & Equivalents (End of Period) | $25,420 | $37,645 | $25,420 | $53,809 |
| Accumulated Deficit | $(313,085) | $(273,726) | $(313,085) | $(273,726) |
Note: Revenue declined due to fewer units sold (8 units in Q2 2025 vs. 13 in Q2 2024), partially offset by higher average selling prices. The company reported a gain of $1.7 million YTD from the change in fair value of warrant liabilities.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 25.8% in Q2 2025 and 30.2% YTD compared to 2024, driven primarily by a reduction in device unit sales.
- Expense Reduction: Operating expenses decreased 13.6% in Q2 2025. Research and Development (R&D) expenses fell 23.8% due to lower headcount and consulting costs. General and Administrative (G&A) expenses dropped 12.7% largely due to reduced stock-based compensation.
- Financing Activity: In February 2025, the company completed a registered direct offering raising approximately $6.0 million gross proceeds, issuing 4.5 million shares and warrants. Additionally, the company utilized its At-The-Market (ATM) program to raise net proceeds of $0.8 million YTD.
- Liquidity: Cash and cash equivalents decreased from $37.6 million at year-end 2024 to $25.4 million at June 30, 2025, reflecting a net cash burn of $12.1 million over the six-month period.
Outlook, Risks, and Management Commentary
- Product Milestones: Management highlighted the May 2025 FDA clearance of the next-generation Swoop® system with Optive AI™ software as a critical milestone, promising improved image quality and faster acquisition times.
- Commercial Strategy: The company plans to expand commercial focus in the second half of 2025 beyond critical care into emergency departments, neurology clinics, and physician offices. International expansion is ongoing in Europe, Canada, Australia, and New Zealand.
- Liquidity and Going Concern: Management states that existing capital resources are expected to fund operations for at least 12 months. However, the company has a history of losses and negative working capital. Future financing through equity or debt is anticipated to be necessary to sustain operations and growth.
- Risks: Key risks include the need for additional financing, reliance on a single-source manufacturer, geopolitical instability, and potential impacts from U.S. trade tariffs. The company also noted the enactment of the "One Big Beautiful Bill Act" (OBBBA) in July 2025, which may impact future tax rates, though the impact was not quantified in this filing.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $25.4 million cash balance against the current burn rate (~$17M operating cash outflow YTD) to confirm the 12-month liquidity assertion.
- Revenue Drivers: Assess the impact of the new Optive AI™ software launch on future unit sales and average selling price (ASP) trends.
- Warrant Liability: Review the volatility of the warrant liability valuation ($1.2 million at June 30, 2025) and its potential impact on future earnings.
- Customer Concentration: Note that four customers represented over 10% of revenue in Q2 2025; monitor the stability of these key accounts.
- Regulatory Status: Confirm the commercial uptake of the newly cleared next-generation system in the U.S. and international markets.